-
公开(公告)号：EP0842947A3
公开(公告)日：2001-12-12
申请号：EP97120661.0
申请日：1991-11-07
申请人： CHIRON CORPORATION
IPC分类号： C07K14/18 , C12N15/40 , A61K39/29 , G01N33/576
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles. Cells bearing a mannose receptor or asialoglycoprotein receptor are capable of being infected with HCV, and supporting culturing of the virus.
-
公开(公告)号：EP0842947A2
公开(公告)日：1998-05-20
申请号：EP97120661.0
申请日：1991-11-07
申请人： CHIRON CORPORATION
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles. Cells bearing a mannose receptor or asialoglycoprotein receptor are capable of being infected with HCV, and supporting culturing of the virus.
摘要翻译： 两种丙型肝炎病毒包膜蛋白（E1和E2）都不表达唾液酸化。 这些蛋白质在低等真核生物或其末端糖基化被阻断的哺乳动物细胞中的重组表达导致与天然HCV糖蛋白更相似的重组蛋白质。 当通过GNA凝集素亲和力分离时，E1和E2蛋白聚集成病毒样颗粒。 具有甘露糖受体或脱唾液酸糖蛋白受体的细胞能够感染HCV，并支持病毒的培养。
-
公开(公告)号：EP1471073A2
公开(公告)日：2004-10-27
申请号：EP04076119.9
申请日：1991-11-07
申请人： CHIRON CORPORATION
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： Two Hepatitis C Virus envelope proteins (El and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles. Cells bearing a mannose receptor or asialoglycoprotein receptor are capable of being infected with HCV, and supporting culturing of the virus.
摘要翻译： 以下要求：（A）选自E1和E2的分离的丙型肝炎病毒（HCV）唾液酸糖蛋白（AG）; （B）HCV AG的纯化方法，其包括（a）使化合物 contg。 具有甘露糖结合蛋白的HCV AG，例如。 刀豆豆素A（ConA）或天竺葵凝集素（GNA）和（b）分离组分的部分。 其结合甘露糖结合蛋白，例如 通过甘露糖洗脱; （c）用于检测HCV AG的存在的测定试剂盒，其包含（a）固体支持物，（b）甘露糖结合蛋白质和（c）对HCV AG特异的抗体，其中抗体和 甘露糖结合蛋白与固体支持物结合; （D）用于确定HCV感染或感染的方法，其中体液样品中的任何HCV都是一致的。 在测定之前通过与甘露糖结合蛋白接触; （E）用用于重组表达HCV AG的载体转化的细胞，其中所述载体包含编码糖基化信号的结构基因，HCV AG，在宿主细胞中可操作并且能调节HCV AG表达的调节序列 和选择标记，其中细胞不唾液酸化糖蛋白; 和（F）减少或消除血浆，血清或其他生物液体中HCV的存在的方法。
-
公开(公告)号：EP0832980A1
公开(公告)日：1998-04-01
申请号：EP97113730.2
申请日：1990-01-22
申请人： CHIRON CORPORATION
CPC分类号： A61K31/70 , C12N15/85 , Y02A50/465
摘要： The present invention provides polynucleotide constructs, e.g. recombinant viral vectors, for treating a host cell for a hyperproliferative disorder or infection by an infectious agent, said infection or hyperproliferative disorder being characterised by a human disease-associated trans-acting regulatory factor capable of regulating expression of genes. In particular, the present invention provides such constructs comprising:
(i) at least two tandem copies of a cis-acting regulatory sequence which are controllable by said trans-acting regulatory factor; and
(ii) an effector gene under the control of said cis-acting regulatory sequence the expression of which renders said cell susceptible to protection or destruction, said effector gene encoding a gene product which is capable of converting a prodrug into its active drug form.摘要翻译： 本发明提供了多核苷酸构建体，例如， 重组病毒载体，用于治疗宿主细胞的过度增殖性疾病或感染因子感染，所述感染或过度增殖性疾病的特征在于能够调节基因表达的人类疾病相关的反式作用调节因子。 特别地，本发明提供了这样的构建体，其包含：（i）至少两个可由所述反式作用调控因子控制的顺式作用调控序列的串联拷贝; 和（ii）在所述顺式作用调节序列控制下的效应基因，所述顺式作用调控序列的表达使得所述细胞易于受到保护或破坏，所述效应基因编码能够将前药转化成其活性药物形式的基因产物。
-
公开(公告)号：EP1471073A3
公开(公告)日：2004-12-01
申请号：EP04076119.9
申请日：1991-11-07
申请人： CHIRON CORPORATION
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： Two Hepatitis C Virus envelope proteins (El and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles. Cells bearing a mannose receptor or asialoglycoprotein receptor are capable of being infected with HCV, and supporting culturing of the virus.
摘要翻译： 两种丙型肝炎病毒包膜蛋白（E1和E2）在没有唾液酸化的情况下表达。 这些蛋白质在低等真核生物中或在终端糖基化被阻断的哺乳动物细胞中的重组表达导致与天然HCV糖蛋白更相似的重组蛋白质。 当通过GNA凝集素亲和力分离时，E1和E2蛋白聚集成病毒样颗粒。 带有甘露糖受体或脱唾液酸糖蛋白受体的细胞能够感染HCV，并支持病毒的培养。
-
公开(公告)号：EP0842947B1
公开(公告)日：2004-04-21
申请号：EP97120661.0
申请日：1991-11-07
申请人： CHIRON CORPORATION
IPC分类号： C07K14/18 , C12N15/40 , A61K39/29 , G01N33/576
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
-
7.发明授权Recombinant therapies for infection and hyperproliferative disorders 失效Rekombinanttherapien感染和过度增生性疾病
公开(公告)号：EP0832980B1
公开(公告)日：2002-06-19
申请号：EP97113730.2
申请日：1990-01-22
申请人： CHIRON CORPORATION
CPC分类号： A61K31/70 , C12N15/85 , Y02A50/465
摘要： The present invention provides polynucleotide constructs, e.g. recombinant viral vectors, for treating a host cell for a hyperproliferative disorder or infection by an infectious agent, said infection or hyperproliferative disorder being characterised by a human disease-associated trans-acting regulatory factor capable of regulating expression of genes. In particular, the present invention provides such constructs comprising: (i) at least two tandem copies of a cis-acting regulatory sequence which are controllable by said trans-acting regulatory factor; and (ii) an effector gene under the control of said cis-acting regulatory sequence the expression of which renders said cell susceptible to protection or destruction, said effector gene encoding a gene product which is capable of converting a prodrug into its active drug form.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
